nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—RET—autonomic nervous system—metabolic syndrome X	0.0179	0.0451	CbGeAlD
Ruxolitinib—BMPR2—artery—metabolic syndrome X	0.0133	0.0336	CbGeAlD
Ruxolitinib—BMPR2—blood vessel—metabolic syndrome X	0.0104	0.0262	CbGeAlD
Ruxolitinib—PRKG2—cardiovascular system—metabolic syndrome X	0.00963	0.0243	CbGeAlD
Ruxolitinib—PRKG2—kidney—metabolic syndrome X	0.00942	0.0238	CbGeAlD
Ruxolitinib—RPS6KA6—cardiovascular system—metabolic syndrome X	0.00863	0.0218	CbGeAlD
Ruxolitinib—PRKCE—adipose tissue—metabolic syndrome X	0.00792	0.02	CbGeAlD
Ruxolitinib—JAK2—blood vessel—metabolic syndrome X	0.00745	0.0188	CbGeAlD
Ruxolitinib—PLK3—cardiovascular system—metabolic syndrome X	0.00721	0.0182	CbGeAlD
Ruxolitinib—PLK3—adipose tissue—metabolic syndrome X	0.00635	0.0161	CbGeAlD
Ruxolitinib—PRKG2—liver—metabolic syndrome X	0.00595	0.015	CbGeAlD
Ruxolitinib—CAMK1—adipose tissue—metabolic syndrome X	0.00594	0.015	CbGeAlD
Ruxolitinib—MARK2—adipose tissue—metabolic syndrome X	0.00577	0.0146	CbGeAlD
Ruxolitinib—PRKCE—liver—metabolic syndrome X	0.00556	0.014	CbGeAlD
Ruxolitinib—JAK1—cardiovascular system—metabolic syndrome X	0.00553	0.014	CbGeAlD
Ruxolitinib—JAK1—kidney—metabolic syndrome X	0.00541	0.0137	CbGeAlD
Ruxolitinib—PLK1—liver—metabolic syndrome X	0.00534	0.0135	CbGeAlD
Ruxolitinib—RPS6KA6—liver—metabolic syndrome X	0.00534	0.0135	CbGeAlD
Ruxolitinib—TAOK2—adipose tissue—metabolic syndrome X	0.00534	0.0135	CbGeAlD
Ruxolitinib—HIPK2—cardiovascular system—metabolic syndrome X	0.00516	0.013	CbGeAlD
Ruxolitinib—HIPK2—kidney—metabolic syndrome X	0.00505	0.0128	CbGeAlD
Ruxolitinib—DAPK3—cardiovascular system—metabolic syndrome X	0.00496	0.0125	CbGeAlD
Ruxolitinib—JAK3—adipose tissue—metabolic syndrome X	0.00491	0.0124	CbGeAlD
Ruxolitinib—JAK1—adipose tissue—metabolic syndrome X	0.00487	0.0123	CbGeAlD
Ruxolitinib—DCLK1—adipose tissue—metabolic syndrome X	0.00487	0.0123	CbGeAlD
Ruxolitinib—ROCK1—cardiovascular system—metabolic syndrome X	0.00476	0.012	CbGeAlD
Ruxolitinib—CAMK1D—adipose tissue—metabolic syndrome X	0.00476	0.012	CbGeAlD
Ruxolitinib—PHKG2—adipose tissue—metabolic syndrome X	0.00473	0.012	CbGeAlD
Ruxolitinib—ROCK1—kidney—metabolic syndrome X	0.00466	0.0118	CbGeAlD
Ruxolitinib—DAPK2—adipose tissue—metabolic syndrome X	0.00465	0.0117	CbGeAlD
Ruxolitinib—DYRK1A—cardiovascular system—metabolic syndrome X	0.00464	0.0117	CbGeAlD
Ruxolitinib—BMPR2—cardiovascular system—metabolic syndrome X	0.00462	0.0117	CbGeAlD
Ruxolitinib—STK16—adipose tissue—metabolic syndrome X	0.00458	0.0116	CbGeAlD
Ruxolitinib—HIPK2—adipose tissue—metabolic syndrome X	0.00455	0.0115	CbGeAlD
Ruxolitinib—DYRK1A—kidney—metabolic syndrome X	0.00454	0.0115	CbGeAlD
Ruxolitinib—BMPR2—kidney—metabolic syndrome X	0.00452	0.0114	CbGeAlD
Ruxolitinib—PLK3—liver—metabolic syndrome X	0.00446	0.0113	CbGeAlD
Ruxolitinib—DAPK3—adipose tissue—metabolic syndrome X	0.00437	0.011	CbGeAlD
Ruxolitinib—CLK2—adipose tissue—metabolic syndrome X	0.00433	0.0109	CbGeAlD
Ruxolitinib—CAMK1—liver—metabolic syndrome X	0.00417	0.0105	CbGeAlD
Ruxolitinib—CAMK2G—cardiovascular system—metabolic syndrome X	0.00414	0.0105	CbGeAlD
Ruxolitinib—DYRK1A—adipose tissue—metabolic syndrome X	0.00409	0.0103	CbGeAlD
Ruxolitinib—BMPR2—adipose tissue—metabolic syndrome X	0.00408	0.0103	CbGeAlD
Ruxolitinib—LRRK2—kidney—metabolic syndrome X	0.00401	0.0101	CbGeAlD
Ruxolitinib—NUAK2—adipose tissue—metabolic syndrome X	0.0039	0.00985	CbGeAlD
Ruxolitinib—TAOK2—liver—metabolic syndrome X	0.00374	0.00946	CbGeAlD
Ruxolitinib—TYK2—cardiovascular system—metabolic syndrome X	0.00366	0.00924	CbGeAlD
Ruxolitinib—BMP2K—adipose tissue—metabolic syndrome X	0.00365	0.00922	CbGeAlD
Ruxolitinib—CAMK2G—adipose tissue—metabolic syndrome X	0.00365	0.00922	CbGeAlD
Ruxolitinib—LRRK2—adipose tissue—metabolic syndrome X	0.00362	0.00914	CbGeAlD
Ruxolitinib—MKNK2—cardiovascular system—metabolic syndrome X	0.00361	0.00912	CbGeAlD
Ruxolitinib—TYK2—kidney—metabolic syndrome X	0.00358	0.00904	CbGeAlD
Ruxolitinib—RET—kidney—metabolic syndrome X	0.00344	0.0087	CbGeAlD
Ruxolitinib—JAK1—liver—metabolic syndrome X	0.00342	0.00864	CbGeAlD
Ruxolitinib—CAMK1D—liver—metabolic syndrome X	0.00334	0.00843	CbGeAlD
Ruxolitinib—JAK2—cardiovascular system—metabolic syndrome X	0.00333	0.0084	CbGeAlD
Ruxolitinib—PHKG2—liver—metabolic syndrome X	0.00332	0.00838	CbGeAlD
Ruxolitinib—MAP3K2—adipose tissue—metabolic syndrome X	0.00331	0.00837	CbGeAlD
Ruxolitinib—MAP3K7—adipose tissue—metabolic syndrome X	0.00328	0.00829	CbGeAlD
Ruxolitinib—JAK2—kidney—metabolic syndrome X	0.00325	0.00822	CbGeAlD
Ruxolitinib—TYK2—adipose tissue—metabolic syndrome X	0.00322	0.00814	CbGeAlD
Ruxolitinib—STK16—liver—metabolic syndrome X	0.00321	0.00811	CbGeAlD
Ruxolitinib—MAP3K3—cardiovascular system—metabolic syndrome X	0.00321	0.0081	CbGeAlD
Ruxolitinib—HIPK2—liver—metabolic syndrome X	0.00319	0.00806	CbGeAlD
Ruxolitinib—IRAK1—adipose tissue—metabolic syndrome X	0.00318	0.00804	CbGeAlD
Ruxolitinib—MKNK2—adipose tissue—metabolic syndrome X	0.00318	0.00804	CbGeAlD
Ruxolitinib—DAPK3—liver—metabolic syndrome X	0.00307	0.00775	CbGeAlD
Ruxolitinib—CLK2—liver—metabolic syndrome X	0.00304	0.00767	CbGeAlD
Ruxolitinib—ROCK1—liver—metabolic syndrome X	0.00294	0.00744	CbGeAlD
Ruxolitinib—JAK2—adipose tissue—metabolic syndrome X	0.00293	0.00741	CbGeAlD
Ruxolitinib—TAOK3—cardiovascular system—metabolic syndrome X	0.00292	0.00738	CbGeAlD
Ruxolitinib—DYRK1A—liver—metabolic syndrome X	0.00287	0.00725	CbGeAlD
Ruxolitinib—BMPR2—liver—metabolic syndrome X	0.00286	0.00723	CbGeAlD
Ruxolitinib—TAOK3—kidney—metabolic syndrome X	0.00286	0.00722	CbGeAlD
Ruxolitinib—MAP3K3—adipose tissue—metabolic syndrome X	0.00283	0.00714	CbGeAlD
Ruxolitinib—NUAK2—liver—metabolic syndrome X	0.00273	0.00691	CbGeAlD
Ruxolitinib—TAOK3—adipose tissue—metabolic syndrome X	0.00258	0.00651	CbGeAlD
Ruxolitinib—CAMK2G—liver—metabolic syndrome X	0.00256	0.00647	CbGeAlD
Ruxolitinib—BMP2K—liver—metabolic syndrome X	0.00256	0.00647	CbGeAlD
Ruxolitinib—LRRK2—liver—metabolic syndrome X	0.00254	0.00641	CbGeAlD
Ruxolitinib—MAP3K2—liver—metabolic syndrome X	0.00232	0.00587	CbGeAlD
Ruxolitinib—MAP3K7—liver—metabolic syndrome X	0.0023	0.00582	CbGeAlD
Ruxolitinib—TYK2—liver—metabolic syndrome X	0.00226	0.00571	CbGeAlD
Ruxolitinib—MKNK2—liver—metabolic syndrome X	0.00223	0.00564	CbGeAlD
Ruxolitinib—IRAK1—liver—metabolic syndrome X	0.00223	0.00564	CbGeAlD
Ruxolitinib—JAK2—liver—metabolic syndrome X	0.00206	0.0052	CbGeAlD
Ruxolitinib—MAP3K3—liver—metabolic syndrome X	0.00198	0.00501	CbGeAlD
Ruxolitinib—TAOK3—liver—metabolic syndrome X	0.00181	0.00457	CbGeAlD
Ruxolitinib—CYP3A4—kidney—metabolic syndrome X	0.000869	0.00219	CbGeAlD
Ruxolitinib—CYP3A4—liver—metabolic syndrome X	0.000549	0.00139	CbGeAlD
Ruxolitinib—ROCK1—Signaling Pathways—AGT—metabolic syndrome X	3.68e-05	6.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—LEP—metabolic syndrome X	3.67e-05	6.07e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—APOE—metabolic syndrome X	3.67e-05	6.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—APOB—metabolic syndrome X	3.66e-05	6.06e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—INS—metabolic syndrome X	3.64e-05	6.03e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—IL6—metabolic syndrome X	3.64e-05	6.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL6—metabolic syndrome X	3.63e-05	6e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—APOA1—metabolic syndrome X	3.63e-05	6e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IRS1—metabolic syndrome X	3.62e-05	6e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—APOE—metabolic syndrome X	3.61e-05	5.97e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—LEP—metabolic syndrome X	3.61e-05	5.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HTR2C—metabolic syndrome X	3.6e-05	5.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD36—metabolic syndrome X	3.6e-05	5.95e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF2—metabolic syndrome X	3.59e-05	5.94e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PTGS2—metabolic syndrome X	3.59e-05	5.94e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCL2—metabolic syndrome X	3.58e-05	5.93e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—TGFB1—metabolic syndrome X	3.57e-05	5.92e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—IL6—metabolic syndrome X	3.57e-05	5.9e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—APOA1—metabolic syndrome X	3.57e-05	5.9e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AGT—metabolic syndrome X	3.55e-05	5.87e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IGF1—metabolic syndrome X	3.52e-05	5.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—LPL—metabolic syndrome X	3.5e-05	5.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CYBA—metabolic syndrome X	3.48e-05	5.77e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF2—metabolic syndrome X	3.48e-05	5.77e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—APOB—metabolic syndrome X	3.48e-05	5.77e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IRS1—metabolic syndrome X	3.45e-05	5.71e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IL6—metabolic syndrome X	3.42e-05	5.65e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GHRL—metabolic syndrome X	3.41e-05	5.65e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCL5—metabolic syndrome X	3.4e-05	5.63e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PLA2G4A—metabolic syndrome X	3.39e-05	5.61e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—APOB—metabolic syndrome X	3.38e-05	5.6e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF2—metabolic syndrome X	3.38e-05	5.59e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—AKT1—metabolic syndrome X	3.35e-05	5.55e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—SERPINE1—metabolic syndrome X	3.35e-05	5.54e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—LPL—metabolic syndrome X	3.33e-05	5.51e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCL5—metabolic syndrome X	3.3e-05	5.47e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—INS—metabolic syndrome X	3.3e-05	5.47e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PLA2G4A—metabolic syndrome X	3.29e-05	5.45e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—AKT1—metabolic syndrome X	3.29e-05	5.45e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APOB—metabolic syndrome X	3.28e-05	5.43e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IRS1—metabolic syndrome X	3.27e-05	5.42e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CRP—metabolic syndrome X	3.24e-05	5.37e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—AKT1—metabolic syndrome X	3.24e-05	5.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CNR1—metabolic syndrome X	3.23e-05	5.35e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—LPL—metabolic syndrome X	3.23e-05	5.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—IL6—metabolic syndrome X	3.23e-05	5.34e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IRS1—metabolic syndrome X	3.22e-05	5.33e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IL6—metabolic syndrome X	3.21e-05	5.32e-05	CbGpPWpGaD
Ruxolitinib—PHKG2—Metabolism—AKT1—metabolic syndrome X	3.2e-05	5.3e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCL5—metabolic syndrome X	3.2e-05	5.3e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NOS3—metabolic syndrome X	3.19e-05	5.29e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—IL6—metabolic syndrome X	3.19e-05	5.28e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PLA2G4A—metabolic syndrome X	3.19e-05	5.28e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—AKT1—metabolic syndrome X	3.15e-05	5.22e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—INS—metabolic syndrome X	3.13e-05	5.19e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—LPL—metabolic syndrome X	3.13e-05	5.19e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCL2—metabolic syndrome X	3.08e-05	5.1e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—INS—metabolic syndrome X	3.08e-05	5.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TGFB1—metabolic syndrome X	3.06e-05	5.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—IL6—metabolic syndrome X	3.04e-05	5.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—SERPINE1—metabolic syndrome X	3.03e-05	5.02e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCL2—metabolic syndrome X	3.03e-05	5.02e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IGF1—metabolic syndrome X	3.03e-05	5.02e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TGFB1—metabolic syndrome X	3e-05	4.96e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IGF1—metabolic syndrome X	2.98e-05	4.93e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FMO3—metabolic syndrome X	2.97e-05	4.92e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—AKT1—metabolic syndrome X	2.96e-05	4.9e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—AKT1—metabolic syndrome X	2.95e-05	4.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—APOE—metabolic syndrome X	2.93e-05	4.85e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CCL2—metabolic syndrome X	2.92e-05	4.83e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL6—metabolic syndrome X	2.92e-05	4.83e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL6—metabolic syndrome X	2.9e-05	4.81e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NOS3—metabolic syndrome X	2.9e-05	4.79e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—APOA1—metabolic syndrome X	2.9e-05	4.79e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—SERPINE1—metabolic syndrome X	2.88e-05	4.76e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TNF—metabolic syndrome X	2.85e-05	4.72e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AGT—metabolic syndrome X	2.85e-05	4.71e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IRS1—metabolic syndrome X	2.83e-05	4.69e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—SERPINE1—metabolic syndrome X	2.83e-05	4.69e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—AKT1—metabolic syndrome X	2.8e-05	4.64e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—LEP—metabolic syndrome X	2.79e-05	4.62e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—APOE—metabolic syndrome X	2.79e-05	4.62e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—IL6—metabolic syndrome X	2.76e-05	4.58e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AGT—metabolic syndrome X	2.76e-05	4.57e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—APOA1—metabolic syndrome X	2.76e-05	4.56e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NOS3—metabolic syndrome X	2.75e-05	4.55e-05	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—AKT1—metabolic syndrome X	2.74e-05	4.53e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—LEP—metabolic syndrome X	2.71e-05	4.48e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—APOE—metabolic syndrome X	2.71e-05	4.48e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NOS3—metabolic syndrome X	2.7e-05	4.47e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL6—metabolic syndrome X	2.69e-05	4.46e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—IL6—metabolic syndrome X	2.69e-05	4.46e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—AKT1—metabolic syndrome X	2.69e-05	4.45e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—IL6—metabolic syndrome X	2.68e-05	4.44e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AGT—metabolic syndrome X	2.68e-05	4.44e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—AKT1—metabolic syndrome X	2.68e-05	4.44e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—APOA1—metabolic syndrome X	2.68e-05	4.43e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL6—metabolic syndrome X	2.67e-05	4.42e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PTGS2—metabolic syndrome X	2.65e-05	4.39e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MLXIPL—metabolic syndrome X	2.65e-05	4.38e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—EPHX2—metabolic syndrome X	2.65e-05	4.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF2—metabolic syndrome X	2.64e-05	4.37e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APOE—metabolic syndrome X	2.63e-05	4.35e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—LEP—metabolic syndrome X	2.63e-05	4.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IRS1—metabolic syndrome X	2.61e-05	4.33e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL6—metabolic syndrome X	2.61e-05	4.32e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—IL6—metabolic syndrome X	2.6e-05	4.31e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—APOA1—metabolic syndrome X	2.6e-05	4.3e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—TGFB1—metabolic syndrome X	2.59e-05	4.29e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOB—metabolic syndrome X	2.56e-05	4.24e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—AKT1—metabolic syndrome X	2.55e-05	4.22e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL5—metabolic syndrome X	2.5e-05	4.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—INS—metabolic syndrome X	2.5e-05	4.14e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TGFB1—metabolic syndrome X	2.5e-05	4.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PLA2G4A—metabolic syndrome X	2.49e-05	4.13e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—G6PC2—metabolic syndrome X	2.49e-05	4.12e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IRS1—metabolic syndrome X	2.49e-05	4.12e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—AKT1—metabolic syndrome X	2.49e-05	4.11e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—AKT1—metabolic syndrome X	2.48e-05	4.11e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—AKT1—metabolic syndrome X	2.48e-05	4.1e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—AKT1—metabolic syndrome X	2.46e-05	4.08e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL6—metabolic syndrome X	2.46e-05	4.07e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—LPL—metabolic syndrome X	2.45e-05	4.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IRS1—metabolic syndrome X	2.42e-05	4e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—AKT1—metabolic syndrome X	2.41e-05	3.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—AKT1—metabolic syndrome X	2.4e-05	3.98e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—INS—metabolic syndrome X	2.38e-05	3.94e-05	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—AKT1—metabolic syndrome X	2.35e-05	3.9e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCL2—metabolic syndrome X	2.34e-05	3.88e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IRS1—metabolic syndrome X	2.34e-05	3.88e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL6—metabolic syndrome X	2.32e-05	3.84e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—AKT1—metabolic syndrome X	2.32e-05	3.83e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—INS—metabolic syndrome X	2.31e-05	3.83e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—AKT1—metabolic syndrome X	2.31e-05	3.82e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF1—metabolic syndrome X	2.3e-05	3.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—IL6—metabolic syndrome X	2.3e-05	3.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SERPINE1—metabolic syndrome X	2.3e-05	3.81e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL6—metabolic syndrome X	2.28e-05	3.77e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCL2—metabolic syndrome X	2.28e-05	3.77e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—AKT1—metabolic syndrome X	2.27e-05	3.76e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—INS—metabolic syndrome X	2.24e-05	3.71e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF1—metabolic syndrome X	2.24e-05	3.7e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCL2—metabolic syndrome X	2.21e-05	3.65e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOS3—metabolic syndrome X	2.2e-05	3.63e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SERPINE1—metabolic syndrome X	2.19e-05	3.62e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF1—metabolic syndrome X	2.17e-05	3.59e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—AKT1—metabolic syndrome X	2.14e-05	3.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—metabolic syndrome X	2.12e-05	3.52e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SERPINE1—metabolic syndrome X	2.12e-05	3.52e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—metabolic syndrome X	2.12e-05	3.51e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—FABP4—metabolic syndrome X	2.12e-05	3.5e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TGFB1—metabolic syndrome X	2.11e-05	3.5e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—metabolic syndrome X	2.1e-05	3.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AGT—metabolic syndrome X	2.09e-05	3.47e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOS3—metabolic syndrome X	2.09e-05	3.46e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—metabolic syndrome X	2.08e-05	3.45e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SERPINE1—metabolic syndrome X	2.06e-05	3.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—LEP—metabolic syndrome X	2.05e-05	3.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOE—metabolic syndrome X	2.05e-05	3.4e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—metabolic syndrome X	2.03e-05	3.37e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOA1—metabolic syndrome X	2.03e-05	3.36e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOS3—metabolic syndrome X	2.03e-05	3.36e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—metabolic syndrome X	2.01e-05	3.32e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HSD11B1—metabolic syndrome X	2.01e-05	3.32e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOS3—metabolic syndrome X	1.97e-05	3.26e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—metabolic syndrome X	1.96e-05	3.24e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—metabolic syndrome X	1.95e-05	3.23e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFB1—metabolic syndrome X	1.92e-05	3.17e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—metabolic syndrome X	1.89e-05	3.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—metabolic syndrome X	1.88e-05	3.11e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IRS1—metabolic syndrome X	1.83e-05	3.03e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFB1—metabolic syndrome X	1.82e-05	3.01e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—metabolic syndrome X	1.8e-05	2.99e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—G6PD—metabolic syndrome X	1.79e-05	2.96e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFB1—metabolic syndrome X	1.79e-05	2.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—INS—metabolic syndrome X	1.75e-05	2.9e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HDAC3—metabolic syndrome X	1.75e-05	2.89e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—metabolic syndrome X	1.74e-05	2.88e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL2—metabolic syndrome X	1.72e-05	2.85e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—metabolic syndrome X	1.71e-05	2.83e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GCKR—metabolic syndrome X	1.71e-05	2.83e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LPA—metabolic syndrome X	1.71e-05	2.83e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1—metabolic syndrome X	1.7e-05	2.81e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLA2G6—metabolic syndrome X	1.65e-05	2.74e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA5—metabolic syndrome X	1.64e-05	2.71e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—metabolic syndrome X	1.61e-05	2.67e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SERPINE1—metabolic syndrome X	1.61e-05	2.67e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—metabolic syndrome X	1.59e-05	2.63e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—metabolic syndrome X	1.58e-05	2.61e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—metabolic syndrome X	1.56e-05	2.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOS3—metabolic syndrome X	1.54e-05	2.54e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TRIB3—metabolic syndrome X	1.52e-05	2.52e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—metabolic syndrome X	1.52e-05	2.51e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—metabolic syndrome X	1.49e-05	2.46e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—metabolic syndrome X	1.47e-05	2.43e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFB1—metabolic syndrome X	1.45e-05	2.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—metabolic syndrome X	1.44e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—metabolic syndrome X	1.44e-05	2.39e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—metabolic syndrome X	1.4e-05	2.32e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFB1—metabolic syndrome X	1.38e-05	2.29e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—metabolic syndrome X	1.37e-05	2.27e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NAMPT—metabolic syndrome X	1.36e-05	2.26e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LIPC—metabolic syndrome X	1.36e-05	2.24e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GCK—metabolic syndrome X	1.36e-05	2.24e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOC3—metabolic syndrome X	1.35e-05	2.23e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—metabolic syndrome X	1.35e-05	2.23e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFB1—metabolic syndrome X	1.34e-05	2.22e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—metabolic syndrome X	1.33e-05	2.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—metabolic syndrome X	1.32e-05	2.18e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CETP—metabolic syndrome X	1.31e-05	2.17e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFB1—metabolic syndrome X	1.3e-05	2.15e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—metabolic syndrome X	1.3e-05	2.15e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—metabolic syndrome X	1.26e-05	2.09e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SCARB1—metabolic syndrome X	1.25e-05	2.07e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—metabolic syndrome X	1.24e-05	2.06e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SREBF1—metabolic syndrome X	1.22e-05	2.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—metabolic syndrome X	1.2e-05	1.98e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—metabolic syndrome X	1.18e-05	1.96e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GOT2—metabolic syndrome X	1.18e-05	1.96e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMGCR—metabolic syndrome X	1.18e-05	1.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—metabolic syndrome X	1.09e-05	1.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—metabolic syndrome X	1.09e-05	1.81e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCA1—metabolic syndrome X	1.05e-05	1.75e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC2A4—metabolic syndrome X	1.05e-05	1.75e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—metabolic syndrome X	1.04e-05	1.72e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GGT1—metabolic syndrome X	1.02e-05	1.69e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GOT1—metabolic syndrome X	1.02e-05	1.69e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFB1—metabolic syndrome X	1.02e-05	1.68e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—metabolic syndrome X	1.01e-05	1.67e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—metabolic syndrome X	1.01e-05	1.67e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—metabolic syndrome X	9.8e-06	1.62e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—metabolic syndrome X	9.61e-06	1.59e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—metabolic syndrome X	9.33e-06	1.54e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—metabolic syndrome X	9.04e-06	1.5e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOB—metabolic syndrome X	8.67e-06	1.43e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLA2G4A—metabolic syndrome X	8.43e-06	1.4e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LPL—metabolic syndrome X	8.28e-06	1.37e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CD36—metabolic syndrome X	7.86e-06	1.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—metabolic syndrome X	7.66e-06	1.27e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARA—metabolic syndrome X	7.31e-06	1.21e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AGT—metabolic syndrome X	7.08e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—metabolic syndrome X	7.07e-06	1.17e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOE—metabolic syndrome X	6.94e-06	1.15e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA1—metabolic syndrome X	6.86e-06	1.13e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—metabolic syndrome X	6.04e-06	1e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—INS—metabolic syndrome X	5.93e-06	9.81e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—metabolic syndrome X	5.43e-06	8.99e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NOS3—metabolic syndrome X	5.2e-06	8.6e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—metabolic syndrome X	4.75e-06	7.87e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—metabolic syndrome X	2.39e-06	3.95e-06	CbGpPWpGaD
